There have been multiple recent developments in drug manufacturers' lawsuits challenging the legality of 340B contract pharmacy requirements.

Multiple Developments in 340B Contract Pharmacy Lawsuits

Sanofi Slams Government’s Contention of Harm to Covered Entities

Drug maker Sanofi last week updated its lawsuit challenging federal 340B contract pharmacy requirements to poke holes in the government’s introduction of, in the government’s words, “over six thousand pages of complaints from covered entities” about Sanofi’s alleged overcharges for 340B covered outpatient drugs. Sanofi’s July 6 brief also favorably cited U.S. Chief District Leonard Stark’s decision last month in the AstraZeneca case to set aside and vacate HHS’s advisory opinion, and U.S. District Judge Sarah Evans Barker’s March 16 decision in Lilly’s case to grant Lilly a preliminary injunction against 340B ADR proceedings against it.

Drug maker Sanofi last week updated its lawsuit challenging federal 340B contract pharmacy requirements to poke holes in the government’s introduction of, in the government’s words, “over six thousand pages of complaints from covered entities” about Sanofi’s alleged overcharges for 340B covered outpatient drugs.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer